Eli Lilly & Co. (LLY)
1363.38
+12.26
(+0.91%)
USD |
NYSE |
Nov 20, 10:00
Eli Lilly Cash from Operations (Quarterly) : 11.40B for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 11.40B |
| June 30, 2026 | 10.69B |
| March 31, 2026 | 5.333B |
| December 31, 2025 | 3.225B |
| September 30, 2025 | 8.836B |
| June 30, 2025 | 3.087B |
| March 31, 2025 | 1.666B |
| December 31, 2024 | 2.474B |
| September 30, 2024 | 3.712B |
| June 30, 2024 | 1.466B |
| March 31, 2024 | 1.166B |
| December 31, 2023 | -311.90M |
| September 30, 2023 | 2.190B |
| June 30, 2023 | 631.90M |
| March 31, 2023 | 1.731B |
| December 31, 2022 | 1.580B |
| September 30, 2022 | 2.185B |
| June 30, 2022 | 820.70M |
| March 31, 2022 | 2.499B |
| December 31, 2021 | 2.156B |
| September 30, 2021 | 1.631B |
| June 30, 2021 | 1.776B |
| March 31, 2021 | 1.697B |
| December 31, 2020 | 1.815B |
| September 30, 2020 | 1.807B |
| Date | Value |
|---|---|
| June 30, 2020 | 2.495B |
| March 31, 2020 | 382.40M |
| December 31, 2019 | 1.964B |
| September 30, 2019 | 1.510B |
| June 30, 2019 | 1.052B |
| March 31, 2019 | 311.30M |
| December 31, 2018 | 1.449B |
| September 30, 2018 | 2.122B |
| June 30, 2018 | 1.518B |
| March 31, 2018 | 436.50M |
| December 31, 2017 | 1.744B |
| September 30, 2017 | 1.881B |
| June 30, 2017 | 1.651B |
| March 31, 2017 | 339.90M |
| December 31, 2016 | 2.117B |
| September 30, 2016 | 1.659B |
| June 30, 2016 | 1.402B |
| March 31, 2016 | -326.90M |
| December 31, 2015 | 804.30M |
| September 30, 2015 | 1.105B |
| June 30, 2015 | 948.60M |
| March 31, 2015 | -84.80M |
| December 31, 2014 | 1.350B |
| September 30, 2014 | 1.691B |
| June 30, 2014 | 1.054B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 7.72B |
| Merck & Co., Inc. | 6.558B |
| Pfizer Inc. | 5.375B |
| Bristol Myers Squibb Co. | 4.181B |
| Structure Therapeutics, Inc. | -101.92M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -8.299B |
| Cash from Financing (Quarterly) | -7.219B |
| Free Cash Flow | 11.69B |
| Free Cash Flow Per Share (Quarterly) | 4.653 |
| Free Cash Flow to Equity (Quarterly) | 9.562B |
| Free Cash Flow to Firm (Quarterly) | 4.400B |
| Free Cash Flow Yield | 0.91% |